We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 2,743

Preliminary Injunction Issued Against DomainTools Spells More Bad News for Domain Name Investigations
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • November 5 2018

Acting to protect online privacy concerns, a district court recently issued a preliminary injunction against DomainTools, LLC enjoining it from


Spotlight on Upcoming Oral Arguments - November 2018
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • November 2 2018

The University of Florida Research Foundation (UFRF) appeals from a Northern District of Florida decision granting GE’s motion to dismiss after


FDA Draft Guidance on Early Drug Development and the Role of Pre-IND Meetings for Rare Diseases
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • November 1 2018

On October 15, 2018, FDA issued draft guidance on Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings. This draft guidance is


A UK Government’s Guidance if No Deal on Brexit Can Be Struck
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • United Kingdom, European Union
  • October 30 2018

The guidance states that absent of a deal on Brexit by March 2019, the UK government will ensure that all existing registered EU trade marks and


FDA Draft Guidance on Verification Systems Under the Drug Supply Chain Security Act for Prescription Drugs
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • October 29 2018

On October 24, 2018, FDA issued draft guidance on verification systems under the Drug Supply Chain Security Act (DSCSA) for prescription drugs. FDA


Error 101: Director Iancu Wants to Clarify Patentable Subject Matter
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • October 25 2018

On September 24, 2018, USPTO Director Andrei Iancu told the Intellectual Property Owners Association (IPO) that examiners, applicants, patent owners


FDA Draft Guidance on Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • October 24 2018

On October 17, 2018, FDA issued draft guidance on Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling


Key IP Developments in the United Kingdom
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • United Kingdom, European Union
  • October 24 2018

UK patent decisions had a big year in 2017, most notably with the Supreme Court decision Actavis v Eli Lilly (2017 UKSC 48). Since a doctrine of


Is it “Natural?” - False Advertising Considerations
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • October 23 2018

False advertising claims involving uses of the term “natural” have spanned the skincare, hair care, cleaning products, and food industries. Two


What Do Sugarfina’s Bento Box, the Heinz Dip & Squeeze, and the Pepperidge Farm Goldfish Have in Common? Design Rights
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • October 22 2018

You are probably familiar with using trademarks, trade secrets and even utility patents to protect culinary innovations. But, you might be surprised